Conjugate Synthesis Platform
How Our New Drug Works Compared to Standard Therapy: Targeting Brain Cancer
Traditional Approach
The Old Way
Drug 1
Drug 2
Drug 1 and Drug 2 follow separate, uncoordinated pathways, often failing to reach the same target locations.
This lack of precision combined with widespread toxicity leads to harmful effects throughout the body and limits clinical success.
Conjugate Approach
The New Way
Drug 1 + 2
CBD
With our innovative conjugate technology, Drug 2 is released precisely at Drug 1's site of action, ensuring both drugs are always present at the same location.
This targeted delivery dramatically reduces toxicity. The effects are localized to the cancer site, sparing the rest of the body from harmful side effects.
The New Way
Advantages of Our Conjugate Platform
Increased Efficacy
- Rapid absorption and distribution
- Enhanced blood-brain barrier crossing
- 10x effectiveness vs. standard of care
Improved Safety
- Decreased systemic toxicity
- Fewer side effects for patients
Platform Versatility
- Patented across multiple drug families
- New IP with existing drug conjugates
- De-risked drug discovery process
Protected Innovation
Our intellectual property portfolio
Patent
US 11877988
Patent
US 12121584
Patent
US 17622319
Patent
AU 2020366257
Partner With Us
We are actively seeking strategic partners and investors to advance our clinical programs.
Get In Touch